Publicacións nas que colabora con José Benito (75)

2013

  1. A model to predict the response to therapy against hepatitis C virus (HCV) including low-density lipoprotein receptor genotype in HIV/HCV-coinfected patients

    Journal of Antimicrobial Chemotherapy, Vol. 68, Núm. 4, pp. 915-921

  2. Analysis of IL28B alleles with virologic response patterns and plasma cytokine levels in HIV/HCV-coinfected patients

    AIDS, Vol. 27, Núm. 2, pp. 163-173

  3. Central memory CD4 T cells are associated with incomplete restoration of the CD4 T cell pool after treatment-induced long-term undetectable HIV viraemia

    Journal of Antimicrobial Chemotherapy, Vol. 68, Núm. 11, pp. 2616-2625

  4. HIV exposed seronegative individuals show antibodies specifically recognizing native HIV envelope glycoprotein

    AIDS, Vol. 27, Núm. 9, pp. 1375-1385

  5. HIV gag-specific immune response mediated by double negative (CD3+CD4-CD8-) T cells in HIV-exposed seronegative individuals

    Journal of Medical Virology, Vol. 85, Núm. 2, pp. 200-209

  6. HLA-E variants are associated with sustained virological response in HIV/hepatitis C virus-coinfected patients on hepatitis C virus therapy

    AIDS, Vol. 27, Núm. 8, pp. 1231-1238

  7. IL28RA polymorphism is associated with early hepatitis C virus (HCV) treatment failure in human immunodeficiency virus-/HCV-coinfected patients

    Journal of Viral Hepatitis, Vol. 20, Núm. 5, pp. 358-366

  8. Identification of a new epitope for HIV-neutralizing antibodies in the gp41 membrane proximal external region by an Env-tailored phage display library

    European Journal of Immunology, Vol. 43, Núm. 2, pp. 499-509

  9. Interferon-stimulated genes are associated with peginterferon/ribavirin treatment response regardless of IL28B alleles in hepatitis C virus/HIV-coinfected patients

    AIDS, Vol. 27, Núm. 5, pp. 687-696

  10. The changing face of hepatitis C in the new era of direct-acting antivirals

    Antiviral Research

  11. Triple combination therapy for hepatitis C with telaprevir exhibits greater early antiviral activity than with boceprevir

    Antiviral Therapy, Vol. 18, Núm. 5, pp. 709-715